These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29909151)

  • 1. Hematogones Predict Better Outcome in Allogeneic Hematopoietic Stem Cell Transplantation Irrespective of Graft Sources.
    Ishio T; Sugita J; Tateno T; Hidaka D; Hayase E; Shiratori S; Okada K; Goto H; Onozawa M; Nakagawa M; Hashimoto D; Kahata K; Fujimoto K; Endo T; Kondo T; Teshima T
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):1990-1996. PubMed ID: 29909151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation.
    Shima T; Miyamoto T; Kikushige Y; Mori Y; Kamezaki K; Takase K; Henzan H; Numata A; Ito Y; Takenaka K; Iwasaki H; Kamimura T; Eto T; Nagafuji K; Teshima T; Kato K; Akashi K
    Blood; 2013 Jan; 121(5):840-8. PubMed ID: 23233661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of hematogones on outcomes of allogeneic hematopoietic stem cell transplantation.
    Doki N; Haraguchi K; Hagino T; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Okuyama Y; Sakamaki H; Ohashi K
    Ann Hematol; 2015 Dec; 94(12):2055-60. PubMed ID: 26336968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
    Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
    Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
    Salhotra A; Mei M; Stiller T; Mokhtari S; Herrera AF; Chen R; Popplewell L; Zain J; Ali H; Sandhu K; Budde E; Nademanee A; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):287-292. PubMed ID: 30227232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
    Yeh AC; Brunner AM; Spitzer TR; Chen YB; Coughlin E; McAfee S; Ballen K; Attar E; Caron M; Preffer FI; Yeap BY; Dey BR
    Biol Blood Marrow Transplant; 2014 May; 20(5):730-4. PubMed ID: 24530972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
    Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
    Devine SM; Owzar K; Blum W; Mulkey F; Stone RM; Hsu JW; Champlin RE; Chen YB; Vij R; Slack J; Soiffer RJ; Larson RA; Shea TC; Hars V; Sibley AB; Giralt S; Carter S; Horowitz MM; Linker C; Alyea EP
    J Clin Oncol; 2015 Dec; 33(35):4167-75. PubMed ID: 26527780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning.
    Akahoshi Y; Kako S; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Nishida J; Kanda Y
    Hematology; 2015 Aug; 20(7):410-5. PubMed ID: 25437012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.
    Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Ann Hematol; 2019 Jul; 98(7):1743-1753. PubMed ID: 31089793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
    Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation.
    Gao L; Liu J; Zhang Y; Chen X; Gao L; Zhang C; Liu Y; Kong P; Zhong J; Sun A; Du X; Su Y; Li H; Liu H; Peng X; Zhang X
    Leuk Res; 2017 Jun; 57():27-36. PubMed ID: 28273549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.
    Ijaz A; Khan AY; Malik SU; Faridi W; Fraz MA; Usman M; Tariq MJ; Durer S; Durer C; Russ A; Parr NNC; Baig Z; Sagar F; Ali Z; McBride A; Anwer F
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):94-99. PubMed ID: 30195074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
    Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.